Homo- and hetero-dimerization of LPA/S1P receptors, G

Biochimica Et Biophysica Acta - Molecular and Cell Biology of L
1761, 1200-1212
DOI: 10.1016/j.bbalip.2006.08.011

Citation Report

#	Article	IF	Citations
1	Mapping Pathways Downstream of Sphingosine 1-Phosphate Subtype 1 by Differential Chemical Perturbation and Proteomics. Journal of Biological Chemistry, 2007, 282, 7254-7264.	1.6	79
2	Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Reviews in Molecular Medicine, 2007, 9, 1-18.	1.6	54
3	Nociceptors of dorsal root ganglion express proton-sensing G-protein-coupled receptors. Molecular and Cellular Neurosciences, 2007, 36, 195-210.	1.0	86
4	S1P-receptors in PC12 and transfected HEK293 cells: Molecular targets of hypotensive imidazoline I1 receptor ligands. Neurochemistry International, 2007, 51, 476-485.	1.9	20
5	Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. European Journal of Clinical Investigation, 2007, 37, 171-179.	1.7	25
6	Lysophosphatidylserine induces calcium signaling through Ki16425/VPC32183-sensitive GPCR in bone marrow-derived mast cells and in C6 glioma and colon cancer cells. Archives of Pharmacal Research, 2008, 31, 310-317.	2.7	7
7	Identification of non-lipid LPA3 antagonists by virtual screening. Bioorganic and Medicinal Chemistry, 2008, 16, 6207-6217.	1.4	29
8	Sphingolipid receptors. Biochemistry (Moscow), 2008, 73, 119-122.	0.7	0
9	Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA1/3, COX-2, and NF-ÍºB activation- and EGFR transactivation-dependent mechanisms. Cellular Signalling, 2008, 20, 1804-1814.	1.7	60
10	Lysophosphatidic acid (LPA)â€induced vasodilatorâ€stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PCâ€3 prostate cancer cells. Molecular Oncology, 2008, 2, 54-69.	2.1	35
11	Sharpening the edges of understanding the structure/function of the LPA1 receptor: Expression in cancer and mechanisms of regulationâ˜†. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 547-557.	1.2	43
12	Lysophosphatidic Acid Receptors Determine Tumorigenicity and Aggressiveness of Ovarian Cancer Cells. Journal of the National Cancer Institute, 2008, 100, 1630-1642.	3.0	186
13	Transcriptional and postâ€transcriptional mechanisms for lysophosphatidic acidâ€induced cyclooxygenaseâ€2 expression in ovarian cancer cells. FASEB Journal, 2008, 22, 2639-2651.	0.2	42
14	Lysophosphatidic Acid can Support the Formation of Membranous Structures and an Increase in MBP mRNA Levels in Differentiating Oligodendrocytes. Neurochemical Research, 2009, 34, 182-193.	1.6	37
15	Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nature Reviews Drug Discovery, 2009, 8, 297-307.	21.5	151
16	Expression and Function of Proton-Sensing G-Protein-Coupled Receptors in Inflammatory Pain. Molecular Pain, 2009, 5, 1744-8069-5-39.	1.0	44
17	Bone marrow mononuclear cells shift bioactive lipid pattern in injured kidney towards tissue repair in rats with unilateral ureteral obstruction. Nephrology Dialysis Transplantation, 2010, 25, 3867-3874.	0.4	16
18	Lipoprotein-Derived Lysophosphatidic Acid Promotes Atherosclerosis by Releasing CXCL1Âfrom the Endothelium. Cell Metabolism, 2011, 13, 592-600.	7.2	176

#	Article	IF	Citations
19	Induction of lysophosphatidic acid receptor-3 by 12-O-tetradecanoylphorbol-13-acetate stimulates cell migration of rat liver cells. Cancer Letters, 2011, 309, 236-242.	3.2	26
20	Loss of lysophosphatidic acid receptor-3 enhances cell migration in rat lung tumor cells. Biochemical and Biophysical Research Communications, 2011, 405, 450-454.	1.0	37
21	The Impact of Bioactive Lipids on Cardiovascular Development. Stem Cells International, 2011, 2011, 1-13.	1.2	23
22	No Involvement of Lysophosphatidic Acid Receptor-3 in Cell Migration of Mouse Lung Tumor Cells Stimulated by 12-O-Tetradecanoylphorbol-13-acetate. Journal of Toxicologic Pathology, 2011, 24, 183-186.	0.3	1
23	Lysophosphatidic acid in atherosclerotic diseases. British Journal of Pharmacology, 2012, 167, 465-482.	2.7	80
24	Opposite roles of LPA1 and LPA3 on cell motile and invasive activities of pancreatic cancer cells. Tumor Biology, 2012, 33, 1739-1744.	0.8	29
25	Negative regulation of cell motile and invasive activities by lysophosphatidic acid receptor-3 in colon cancer HCT116 cells. Tumor Biology, 2012, 33, 1899-1905.	0.8	12
26	Constitutively active lysophosphatidic acid receptor-1 enhances the induction of matrix metalloproteinase-2. Biochemical and Biophysical Research Communications, 2012, 417, 790-793.	1.0	24
27	Lysophosphatidic acid receptorâ€3 increases tumorigenicity and aggressiveness of rat hepatoma RH7777 cells. Molecular Carcinogenesis, 2013, 52, 247-254.	1.3	33
28	The structure and function of the S1P1 receptor. Trends in Pharmacological Sciences, 2013, 34, 401-412.	4.0	104
29	Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells. Microvascular Research, 2013, 85, 59-67.	1.1	28
30	Application of in Utero Electroporation of G-Protein Coupled Receptor (GPCR) Genes, for Subcellular Localization of Hardly Identifiable GPCR in Mouse Cerebral Cortex. Molecules and Cells, 2014, 37, 554-561.	1.0	4
31	Lysophosphatidic acid receptor-5 negatively regulates cell motile and invasive activities of human sarcoma cell lines. Molecular and Cellular Biochemistry, 2014, 393, 17-22.	1.4	12
32	Interference with distinct steps of sphingolipid synthesis and signaling attenuates proliferation of U87MG glioma cells. Biochemical Pharmacology, 2015, 96, 119-130.	2.0	31
33	G protein-coupled receptors Flop1 and Flop2 inhibit Wnt/Î²-catenin signaling and are essential for head formation in Xenopus. Developmental Biology, 2015, 407, 131-144.	0.9	7
34	GGIP: Structure and sequence-based GPCR-GPCR interaction pair predictor. Proteins: Structure, Function and Bioinformatics, 2016, 84, 1224-1233.	1.5	13
35	Positive and Negative Cross-Talk between Lysophosphatidic Acid Receptor 1, Free Fatty Acid Receptor 4, and Epidermal Growth Factor Receptor in Human Prostate Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 124-133.	1.3	21
36	Heteromerization of G2A and OGR1 enhances proton sensitivity and proton-induced calcium signals. Journal of Receptor and Signal Transduction Research, 2016, 36, 633-644.	1.3	19

#	Article	IF	Citations
37	Mechanisms of sphingosine 1-phosphate receptor signalling in cancer. Cellular Signalling, 2017, 34, 66-75.	1.7	69
38	Selective export of autotaxin from the endoplasmic reticulum. Journal of Biological Chemistry, 2017, 292, 7011-7022.	1.6	15
39	The role of free-fatty acid receptor-4 (FFA4) in human cancers and cancer cell lines. Biochemical Pharmacology, 2018, 150, 170-180.	2.0	33
40	Platelets, autotaxin and lysophosphatidic acid signalling: winâ€win factors for cancer metastasis. British Journal of Pharmacology, 2018, 175, 3100-3110.	2.7	39
41	Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside. Cancers, 2019, 11, 1523.	1.7	35
42	GPR68: An Emerging Drug Target in Cancer. International Journal of Molecular Sciences, 2019, 20, 559.	1.8	66
43	Lysophosphatidic Acid Signaling in Diabetic Nephropathy. International Journal of Molecular Sciences, 2019, 20, 2850.	1.8	41
44	Constraints on GPCR Heterodimerization Revealed by the Type-4 Induced-Association BRET Assay. Biophysical Journal, 2019, 116, 31-41.	0.2	13
45	Sphingosine-1 phosphate induces cAMP/PKA-independent phosphorylation of the cAMP response element-binding protein (CREB) in granulosa cells. Molecular and Cellular Endocrinology, 2021, 520, 111082.	1.6	11
46	Lipid rafts as platforms for sphingosine 1-phosphate metabolism and signalling. Cellular Signalling, 2021, 80, 109929.	1.7	13
47	The LPA3 Receptor: Regulation and Activation of Signaling Pathways. International Journal of Molecular Sciences, 2021, 22, 6704.	1.8	6
48	Proton-Sensing GPCRs in Health and Disease. Cells, 2021, 10, 2050.	1.8	24
49	Interactions between lysophosphatidylinositol receptor GPR55 and sphingosine-1-phosphate receptor S1P5 in live cells. Biochemical and Biophysical Research Communications, 2021, 570, 53-59.	1.0	5
50	Regulation of T Cell Motility In Vitro and In Vivo by LPA and LPA2. PLoS ONE, 2014, 9, e101655.	1.1	52
51	FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer. Oncotarget, 2015, 6, 27688-27699.	0.8	40
52	Oligomerization of the Heptahelical G Protein Coupling Receptors: A Case for Association Using Transmembrane Helices (Supplimentry Material). Mini-Reviews in Medicinal Chemistry, 2009, 9, 329-339.	1.1	8
53	Class A Orphans (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	8
55	Class A Orphans (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0

#	Article	IF	Citations
56	Physiological relevance of proton-activated GPCRs. Pflugers Archiv European Journal of Physiology, 2022, 474, 487-504.	1.3	16
57	Platelet-Derived S1P and Its Relevance for the Communication with Immune Cells in Multiple Human Diseases. International Journal of Molecular Sciences, 2022, 23, 10278.	1.8	3
58	Plasma metabolic profiling implicates dysregulated lipid metabolism and glycolytic shift in hyperinflammatory ARDS. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L297-L306.	1.3	7